Serum cytochrome c and m30-neoepitope of cytokeratin-18 in chronic hepatitis C

Liver International

Volumn 34, Issue 4, 2014, Pages 544-550

  Parfieniuk Kowerda, Anna ^a   Lapinski, Tadeusz W ^a   Rogalska Plonska, Magdalena ^a   Swiderska, Magdalena ^a   Panasiuk, Anatol ^a   Jaroszewicz, Jerzy ^a   Flisiak, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic hepatitis C; HCV; Serum cytochrome c; Serum cytokeratin 18; Serum M30 CK18; Sustained virological response

Indexed keywords

CYTOCHROME C; CYTOKERATIN 18; CYTOKERATIN 18 M30 NEOEPITOPE; EPITOPE; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; YOUNG ADULT;

CHRONIC HEPATITIS C; HCV; SERUM CYTOCHROME C; SERUM CYTOKERATIN-18; SERUM M30-CK18; SUSTAINED VIROLOGICAL RESPONSE;

ADULT; AGED; ANALYSIS OF VARIANCE; APOPTOSIS; CYTOCHROMES C; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KERATIN-18; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; STATISTICS, NONPARAMETRIC;

EID: 84895801877     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12297     Document Type: Article

References (37)

1. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43: 550-2.
2. Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18: 7719-30.
3. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
4. Golstein P, Ojcius DM, Young JD. Cell death mechanisms and the immune system. Immunol Rev 1991; 121: 29-65.
5. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. Faseb J 1995; 9: 1277-87.
6. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108: 567-74.
7. Stegmann KA, Bjorkstrom NK, Veber H, et al. Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138: 1885-97.
8. Fischer R, Baumert T, Blum HE. Hepatitis C virus infection and apoptosis. World J Gastroenterol 2007; 13: 4865-72.
9. Panasiuk A, Parfieniuk A, Zak J, Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int 2009; 30: 472-8.
10. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nat Cell Biol 2000; 2: 156-62.
11. Zhao P, Han T, Guo JJ, et al. HCV NS4B induces apoptosis through the mitochondrial death pathway. Virus Res 2012; 169: 1-7.
12. Chu PG, Lau SK, Weiss LM. Keratin expression in endocrine organs and their neoplasms. Endocr Pathol 2009; 20: 1-10.
13. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-39.
14. Leers MP, Kolgen W, Bjorklund V, et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 1999; 187: 567-72.
15. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 2004; 297: 11-26.
16. Linder S, Havelka A M, Ueno T, Shoshan M C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004; 214: 1-9.
17. Biven K, Erdal H, Hagg M, et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 2003; 8: 263-8.
18. Ueno T, Toi M, Biven K, et al. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003; 39: 769-74.
19. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
20. Ben-Ari Z, Schmilovotz-Weiss H, Belinki A, et al. Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J Intern Med 2003; 254: 168-75.
21. Osaka A, Hasegawa H, Tsuruda K, et al. Serum cytochrome c to indicate the extent of ongoing tumor cell death. Int J Lab Hematol 2009; 31: 307-14.
22. Tafani M, Karpinich NO, Hurster KA, et al. Cytochrome c release upon Fas receptor activation depends on translocation of full-length bid and the induction of the mitochondrial permeability transition. J Biol Chem 2002; 277: 10073-82.
23. Gremion C, Grabscheid B, Wolk B, et al. Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 2004; 78: 2152-7.
24. Iken K, Huang L, Bekele H, Schmidt EV, Koziel MJ. Apoptosis of activated CD4 + and CD8 + T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology 2006; 346: 363-72.
25. Sakaida I, Kimura T, Yamasaki T, et al. Cytochrome c is a possible new marker for fulminant hepatitis in humans. J Gastroenterol 2005; 40: 179-85.
26. Ueno T, Toi M, Linder S. Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 2005; 59(Suppl 2): S359-62.
27. Bantel H, Lugering A, Heidemann J, et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40: 1078-87.
28. Volkmann X, Cornberg M, Wedemeyer H, et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. Hepatology 2006; 43: 1311-6.
29. Yagmur E, Trautwein C, Leers MP, Gressner AM, Tacke F. Elevated apoptosis-associated cytokeratin 18 fragments (CK18Asp386) in serum of patients with chronic liver diseases indicate hepatic and biliary inflammation. Clin Biochem 2007; 10: 651-5.
30. Valva P, De Matteo E, Galoppo MC, Gismondi MI, Preciado MV. Apoptosis markers related to pathogenesis of pediatric chronic hepatitis C virus infection: M30 mirrors the severity of steatosis. J Med Virol 2010; 82: 949-57.
31. Jazwinski A B, Thompson a J, Clark PJ, et al. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. J Viral Hepat 2012; 19: 278-82.
32. Valva P, Casciato P, Lezama C, et al. Serum apoptosis markers related to liver damage in chronic heptitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS ONE 2013; 8: e53519.
33. Mcpartland JL, Guzail MA, Kendall CH, Pringle JH. Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody. Int J Exp Pathol 2005; 86: 19-24.
34. Hetz H, Hoetzenecker K, Hacker S, et al. Caspase-cleaved cytokeratin 18 and 20 S proteasome in liver degeneration. J Clin Lab Anal 2007; 21: 277-81.
35. Simopoulos C, Tsaroucha AK, Asimakopoulos B, et al. Total and caspase-cleaved cytokeratin 18 in chronic cholecystitis: a prospective study. BMC Gastroenterol 2008; 8: 14.
36. Makin G, Dive C. Apoptosis and cancer chemotherapy. Trends Cell Biol 2001; 11: S22-6.
37. Cummings J, Hodgkinson C, Odedra R, et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol Cancer Ther 2008; 7: 455-63.